Tubulis Technologies

Tubulis Technologies is currently a pre-start-up project affiliated with the Ludwig Maximilians University (LMU) Munich and the Leibniz-Institut für Molekulare Pharmakologie (FMP) Berlin. Tubulis Technologies aims to provide the next generation of highly defined, effective and stable ADCs. The company will focus on the development of cutting-edge technologies for site-specific antibody conjugation, thereby providing the ‘molecular glue’ for efficient drug attachment. For this purpose, we integrate biotechnological and chemical expertises with proprietary know how to promote ADC homogeneity and overall stability, ultimately widening the therapeutic window for ADCs.